The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

John B. Porter

UCL Cancer Institute

Department of Haematology

University College London

72 Huntley Street

UK

[email]@ucl.ac.uk

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • UCL Cancer Institute, Department of Haematology, University College London, 72 Huntley Street, UK. 1997 - 2013
  • Department of Hematology, University College London, UCL Cancer Institute, Paul O'Gorman Building, Turkey. E- mail:. 2012
  • University College London, London, UK. 2008 - 2011
  • Red Cell Disorders Unit, University College London Hospital, 250 Euston Road, London, UK. 2010
  • University College London, Department of Haematology, London, UK. 2005
  • University College London, Thalassaemia and Sickle Unit UCL Hospitals, London, UK. 2001

References

  1. Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy. Porter, J.B., Elalfy, M.S., Taher, A.T., Aydinok, Y., Chan, L.L., Lee, S.H., Sutcharitchan, P., Habr, D., Martin, N., El-Beshlawy, A. Ann. Hematol. (2013) [Pubmed]
  2. Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response. Aydinok, Y., Evans, P., Manz, C.Y., Porter, J.B. Haematologica (2012) [Pubmed]
  3. Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias. Porter, J.B., Lin, K.H., Beris, P., Forni, G.L., Taher, A., Habr, D., Domokos, G., Roubert, B., Thein, S.L. Eur. J. Haematol. (2011) [Pubmed]
  4. Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies. Porter, J.B., Shah, F.T. Hematol. Oncol. Clin. North Am. (2010) [Pubmed]
  5. Deferasirox--current knowledge and future challenges. Porter, J.B. Ann. N. Y. Acad. Sci. (2010) [Pubmed]
  6. Optimizing iron chelation strategies in beta-thalassaemia major. Porter, J.B. Blood Rev. (2009) [Pubmed]
  7. Deferasirox: an update. Porter, J.B. Hemoglobin (2009) [Pubmed]
  8. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Porter, J., Galanello, R., Saglio, G., Neufeld, E.J., Vichinsky, E., Cappellini, M.D., Olivieri, N., Piga, A., Cunningham, M.J., Soulières, D., Gattermann, N., Tchernia, G., Maertens, J., Giardina, P., Kwiatkowski, J., Quarta, G., Jeng, M., Forni, G.L., Stadler, M., Cario, H., Debusscher, L., Della Porta, M., Cazzola, M., Greenberg, P., Alimena, G., Rabault, B., Gathmann, I., Ford, J.M., Alberti, D., Rose, C. Eur. J. Haematol. (2008) [Pubmed]
  9. Concepts and goals in the management of transfusional iron overload. Porter, J.B. Am. J. Hematol. (2007) [Pubmed]
  10. Deferasirox: An effective once-daily orally active iron chelator. Porter, J.B. Drugs. Today (2006) [Pubmed]
  11. Monitoring and treatment of iron overload: state of the art and new approaches. Porter, J.B. Semin. Hematol. (2005) [Pubmed]
  12. Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use. Porter, J.B., Rafique, R., Srichairatanakool, S., Davis, B.A., Shah, F.T., Hair, T., Evans, P. Ann. N. Y. Acad. Sci. (2005) [Pubmed]
  13. Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. Porter, J.B., Davis, B.A. Best. Pract. Res. Clin. Haematol (2002) [Pubmed]
  14. Practical management of iron overload. Porter, J.B. Br. J. Haematol. (2001) [Pubmed]
  15. A trial to investigate the relationship between DFO pharmacokinetics and metabolism and DFO-related toxicity. Porter, J.B., Faherty, A., Stallibrass, L., Brookman, L., Hassan, I., Howes, C. Ann. N. Y. Acad. Sci. (1998) [Pubmed]
  16. A risk-benefit assessment of iron-chelation therapy. Porter, J.B. Drug. Saf (1997) [Pubmed]
 
WikiGenes - Universities